MedWatch

Veloxis hires chief scientific officer from BMS

The Danish biotech company Veloxis has hired a new chief science officer to manage the company's regulatory and medical affairs departments. The new CSO joins Veloxis from a position in US-based Bristol-Myers Squibb.

Veloxis has appointed Ulf Meier-Kriesche as its Chief Scientific Officer and he will oversee the Danish company’s regulatory and medical affairs departments. This is according to a press release from Veloxis.

The new CSO is a board certified nephrologist, specialist in medical kidney diseases, with more than 20 years of practical clinical experience in transplantation. And this is also the main focus for Veloxis’, as its main asset Envarus XR is used to prevent organ rejection in patients who have undergone a kidney or liver transplantation.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier